

## ***MolMed: the CAR-T CD44v6 clinical trial progress presented at the 2<sup>nd</sup> European CAR T Cell Meeting in Sitges, Barcelona.***

Milan (Italy), February 3<sup>rd</sup> 2020 - MolMed S.p.A. (MLMD.MI), a biotechnology company focused on research, development, manufacturing and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases, took part at the 2<sup>nd</sup> European CAR T Cell Meeting in Sitges, Barcelona, an event entirely focused on CAR T therapies and promoted by the two main organizations dedicated to the treatment of blood cancers: the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA). The conference brought together haematologists, oncologists, companies in the field and patient organizations representatives from all over the world, in order to assess the research advancement, promote preclinical and clinical initiatives at the European level, and raise awareness on the potential value of this new class of therapies among all the stakeholders involved.

The conference program, which aimed at offering a comprehensive outlook on the current research efforts in Europe, USA and Asia and giving updates on the rapid developments of these innovative therapies, included the speech by Professor Fabio Ciceri, Principal Investigator of the EURE-CART program. On Saturday 1<sup>st</sup> professor Ciceri presented the CAR T CD44v6 clinical study, currently underway in Acute Myeloid Leukemia and Multiple Myeloma indications. The presentation focused on the most innovative features of CAR T CD44v6 clinical protocol together with the regulatory and operating issues encountered during the implementation of the study with the regulatory authorities of the European countries involved: Italy, Germany, Spain and Czech Republic.

Professor Ciceri also provided an update on the clinical trial: since the end of September 2019, 4 patients were enrolled, 3 at the IRCCS San Raffaele Hospital in Milan and 1 at the Fakultni Nemocnice S Poliklinikou in Ostrava (Czech Republic). Among them 1 resulted eligible for treatment and was infused at the end of December at the IRCCS San Raffaele Hospital in Milan at the minimum dosage required by the dose escalation protocol (entry level) of phase I/II. To date, the patient has not experienced any adverse reactions attributable to the experimental therapy.

Finally, patients' identification and selection continues at the centres participating in the study in order to increase the number of subjects treated, verify the safety and therapeutic activity of the CAR-T CD44v6 and identify the optimal dose.

On the sidelines of his speech, Professor Ciceri said *"I am satisfied that the study has finally started in Italy and in the Czech Republic and I hope that it could start soon also in Germany and Spain, in order to have a contribution to the enrollment by all the countries participating in this innovative project, which is supported by a grant from the European Commission"*.



PRESS RELEASE

### *About MolMed*

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed's is also developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. The product, whose innovative spacer incorporated in the CAR protein received in May 2019 the confirmation of grant, is potentially effective also in several epithelial solid tumors. MolMed is also developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

### *For further information:*

**Ilaria Candotti**

*Investor Relations & Communication Manager*

MolMed S.p.A.

+39 02 21277.205

[investor.relations@molmed.com](mailto:investor.relations@molmed.com)

**Tommasina Cazzato**

*Press Office*

Community Group

+39 345 7357751

[tommasina.cazzato@communitygroup.it](mailto:tommasina.cazzato@communitygroup.it)